Compare Tilray Brands Inc (TLRY) vs 22nd Century Group Inc (XXII) Price & Performance

TLRY trades at $4.23, down 1.63% on the day, with a bearish technical signal and negative earnings trends. The company reported a net loss of $2.19 billion in 2025 despite revenue growth to $821.31 million, reflecting deep profitability challenges. Analysts show cautious sentiment with 65% hold ratings, while recent news highlights expansion in medical cannabis and beverage segments amid ongoing regulatory uncertainty.

The outlook remains challenged by persistent losses and high debt-to-asset ratio of 12.25, though low P/S and P/B ratios suggest undervaluation. Key risks include profitability execution and federal cannabis policy shifts, while potential catalysts lie in international expansion and cost management improvements.

XXII trades at $4.32, down 0.23% on the day, with neutral technical signals and bearish moving averages. The company shows significant financial challenges with negative profit margins (-65.76% net income margin) and declining revenue, though analyst sentiment remains positive with 75% buy ratings. Recent corporate actions include a 20:1 reverse stock split completed in June 2026, while expansion initiatives in California and New York aim to drive VLN brand growth.

The outlook remains speculative with high execution risk given persistent losses and negative ROE (-130.19%). Investment opportunity hinges on successful commercialization of reduced-nicotine products and FDA regulatory progress, but substantial financial deterioration and competitive pressures present significant downside risk for shareholders.